HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Desh Rakshak Aushdhalaya Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Desh Rakshak Aushdhalaya Ltd Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 768.7 as of 05 May 15:30 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Desh Rakshak Aushdhalaya Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Desh Rakshak Aushdhalaya Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Desh Rakshak Aushdhalaya Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Desh Rakshak Aushdhalaya Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Desh Rakshak Aushdhalaya Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Desh Rakshak Aushdhalaya Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
  • The company is engaged in pharmaceuticals business.
  • As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Desh Rakshak Aushdhalaya Ltd

  • The flagship company Desh Rakshak Aushdhalaya Limited of Bhagwant Group was originally started in 1901 as a proprietoryship Concern by late Shri Bhagwant Rai Jain, a well renowned Vaidya Father of Late Dr. Paras Kumar Jain, Ex Chairman & Managing Director of the Company.
  • The Concern was converted into a Private Limited Company in Jul.'94. Desh Rakshakare the oldest manufacturer of Pure Ayurvedic and Herbal Products as discovered by the Ancient Seers & Sages.
  • The medicines are categorized into Proprietary & Classical Medicines.
  • They are currently manufacturing around 450 products (Proprietary & Classical mix) and all of these medicines are manufactured as per the prescribed norms and standards of the Indian Government.
  • The Company has been manufacturing ayurvedic medicines with traditional processes.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Desh Rakshak Aushdhalaya Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 15,109 Cr while Market cap of Desh Rakshak Aushdhalaya Ltd is 13 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd?

As of May 5, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹768.7. On the other hand, Desh Rakshak Aushdhalaya Ltd stock price is INR ₹23.62.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions